TY - JOUR
T1 - Granulocyte colony-stimulating factor does not improve mortality in severe alcoholic hepatitis
T2 - A single-center experience from the United States
AU - Nahas, Jonathan
AU - Tow, Clara Y.
AU - Chacko, Kristina R.
AU - Haider, Tehseen
AU - Massoumi, Hatef
N1 - Publisher Copyright:
© 2023, Gastroenterology and Hepatology From Bed to Bench (GHFBB).
PY - 2023
Y1 - 2023
N2 - Aim: To assess the role of granulocyte colony-stimulating factor (GCSF) in the patients with severe alcoholic hepatitis (SAH) using real world experience in the United States. Background: There are few effective treatments for severe alcoholic hepatitis, which has a significant fatality rate. GCSF has been associated with improved survival in a small number of Indian studies, while there is a dearth of information from other parts of the globe. Methods: We performed a single-center retrospective study of consecutive patients admitted to a tertiary care, liver transplant center with severe alcoholic hepatitis from May 2015 to February 2019. The patients receiving GCSF (5µg/kg subcutaneously every 12 hours for 5 consecutive days) (n=12) were compared to the patients receiving standard of care (n=42). Results: Thirty-day, 90-day and 1-year mortality rates was similar among groups (25% vs. 17%, P=0.58; 41% vs 29%, P=0.30; 41% vs 47%, P=0.44, respectively). There was no difference in liver transplant listing and orthotopic transplantation among groups. Conclusion: In this real-world, United States-based study, GCSF does not improved survival in the patient with several alcoholic hepatitis compared to standard of care.
AB - Aim: To assess the role of granulocyte colony-stimulating factor (GCSF) in the patients with severe alcoholic hepatitis (SAH) using real world experience in the United States. Background: There are few effective treatments for severe alcoholic hepatitis, which has a significant fatality rate. GCSF has been associated with improved survival in a small number of Indian studies, while there is a dearth of information from other parts of the globe. Methods: We performed a single-center retrospective study of consecutive patients admitted to a tertiary care, liver transplant center with severe alcoholic hepatitis from May 2015 to February 2019. The patients receiving GCSF (5µg/kg subcutaneously every 12 hours for 5 consecutive days) (n=12) were compared to the patients receiving standard of care (n=42). Results: Thirty-day, 90-day and 1-year mortality rates was similar among groups (25% vs. 17%, P=0.58; 41% vs 29%, P=0.30; 41% vs 47%, P=0.44, respectively). There was no difference in liver transplant listing and orthotopic transplantation among groups. Conclusion: In this real-world, United States-based study, GCSF does not improved survival in the patient with several alcoholic hepatitis compared to standard of care.
KW - Alcoholic hepatitis
KW - Granulocyte colony-stimulating factor
KW - Liver failure
UR - http://www.scopus.com/inward/record.url?scp=85167399321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85167399321&partnerID=8YFLogxK
U2 - 10.22037/ghfbb.v16i1.2639
DO - 10.22037/ghfbb.v16i1.2639
M3 - Article
AN - SCOPUS:85167399321
SN - 2008-2258
VL - 16
SP - 90
EP - 92
JO - Gastroenterology and Hepatology from Bed to Bench
JF - Gastroenterology and Hepatology from Bed to Bench
IS - 1
ER -